Regency Lifesciences (India) Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 23-12-2024
- Paid Up Capital ₹ 1.00 M
as on 23-12-2024
- Company Age 15 Year, 8 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.50 M
as on 23-12-2024
- Revenue 31.24%
(FY 2022)
- Profit 25.63%
(FY 2022)
- Ebitda 20.01%
(FY 2022)
- Net Worth 32.07%
(FY 2022)
- Total Assets -2.88%
(FY 2022)
About Regency Lifesciences (India)
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹5.50 M.
Abel Alexander, Balu Durgaprasad, and Jeslet Abel serve as directors at the Company.
- CIN/LLPIN
U24231KA2009PTC051931
- Company No.
051931
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Dec 2009
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Regency Lifesciences (India)?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Abel Alexander  | Managing Director | 23-Dec-2009 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Balu Durgaprasad | Director | 02-Jan-2015 | Current |
| Jeslet Abel | Director | 28-Jun-2019 | Current |
Financial Performance of Regency Lifesciences (India).
Regency Lifesciences (India) Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 31.24% increase. The company also saw a substantial improvement in profitability, with a 25.63% increase in profit. The company's net worth Soared by an impressive increase of 32.07%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Regency Lifesciences (India)?
In 2022, Regency Lifesciences (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Indian Overseas Bank Creation Date: 04 Oct 2022 | ₹5.50 M | Open |
How Many Employees Work at Regency Lifesciences (India)?
Unlock and access historical data on people associated with Regency Lifesciences (India), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Regency Lifesciences (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Regency Lifesciences (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
